2m 2m 2m 2m 2m 2m 2m
KAIROS PHARMA (KAPA)
NYSE
$0.47+$0.007 (+1.43%)
Price as of Jun 03, 2026 7:28 PM EDT- $10.9MMarket Cap
- -11.18%1-Year Change
- BiotechnologyIndustry
KAIROS PHARMA (KAPA)
$0.47+$0.007 (+1.43%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -2.1M +415.70% | -414,000 N/A | |
Depreciation and Amortization Expense | 160,000 +158.06% | 62,000 N/A | |
Total Operating Expenses | 5.6M +137.81% | 2.3M N/A | |
Operating Profit | -5.6M +137.81% | -2.3M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 125,000 +148.08% | -260,000 N/A | |
Income before Taxes | -5.6M +137.81% | -2.3M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | N/A N/A | N/A N/A | |
Net Income from Continuing Operations Applicable to Common | N/A N/A | N/A N/A | |
Basic EPS and Net Income | -0.30 +30.43% | -0.23 N/A | |
Diluted EPS and Net Income | -0.30 +30.43% | -0.23 N/A | |
Basic Weighted Average Shares | 18.4M +62.27% | 11.4M N/A | |
Diluted Weighted Average Shares | 18.4M +62.27% | 11.4M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 4.5M +253.07% | 1.3M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 4.5M +253.07% | 1.3M N/A | |
Total Current Assets | 5.4M +29.22% | 4.2M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | 1.2M -27.89% | 1.6M N/A | |
Total Assets | 6.5M +13.38% | 5.8M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 792,000 -63.49% | 2.2M N/A | |
Total Current Liabilities | 199,000 -79.94% | 992,000 N/A | |
Total Long-Term Debt | 675,000 -23.73% | 885,000 N/A | |
Total Long-Term Liabilities | N/A N/A | N/A N/A | |
Total Liabilities | 199,000 -79.94% | 992,000 N/A | |
Retained Earnings | -14.3M +61.79% | -8.8M N/A | |
Total Stockholders Equity | 6.3M +32.77% | 4.8M N/A | |
Total Shares Outstanding | 20.8M +51.58% | 13.7M N/A | |
Cash Flow | |||
Cash from Operating Activities | -3.4M -13.00% | -4.0M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 6.7M +29.72% | 5.1M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | N/A N/A | N/A N/A | |
Return on Equity | N/A N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 27.07 N/A | N/A N/A | |
Cash Ratio | 22.57 N/A | N/A N/A | |
Debt-to-Equity Ratio | 0.23 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.22 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow